The PE Ratio as of November 2024 (TTM) for TScan Therapeutics, Inc. (TCRX) is -4.48

According to TScan Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.48. This represents a change of -24.09% compared to the average of -5.90 of the last 4 quarters.

TScan Therapeutics, Inc. (TCRX) Historical PE Ratio (quarterly & annually)

How has TCRX PE Ratio performed in the past?

The mean historical PE Ratio of TScan Therapeutics, Inc. over the last ten years is -7.42. The current -4.48 PE Ratio has changed 5.94% with respect to the historical average. Over the past ten years (40 quarters), TCRX's PE Ratio was at its highest in in the December 2019 quarter at 0. The PE Ratio was at its lowest in in the March 2020 quarter at -11.35.

TScan Therapeutics, Inc. (TCRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of TScan Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

TScan Therapeutics, Inc. (TCRX) Average PE Ratio

How has TCRX PE Ratio performed in the past?

The current PE Ratio of TScan Therapeutics, Inc. (TCRX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

TScan Therapeutics, Inc. (TCRX) PE Ratio vs. Peers

How is TCRX’s PE Ratio compared to its peers?

TScan Therapeutics, Inc.’s PE Ratio is greater than VectivBio Holding AG (-7.94), greater than Icosavax, Inc. (-15.78), greater than Apellis Pharmaceuticals, Inc. (-15.24), less than iTeos Therapeutics, Inc. (-2.96), greater than Day One Biopharmaceuticals, Inc. (-15.73), less than Acumen Pharmaceuticals, Inc. (-1.74), less than X4 Pharmaceuticals, Inc. (-4.05), less than Inozyme Pharma, Inc. (-1.84), less than Cognition Therapeutics, Inc. (-0.50), less than TFF Pharmaceuticals, Inc. (-0.08), less than Cue Biopharma, Inc. (-1.17), less than Dermata Therapeutics, Inc. (-0.16), greater than ProQR Therapeutics N.V. (-11.90), greater than Annexon, Inc. (-6.12), less than Arrowhead Pharmaceuticals, Inc. (-4.27), greater than Terns Pharmaceuticals, Inc. (-5.12),

Build a custom stock screener for TScan Therapeutics, Inc. (TCRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TScan Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

TScan Therapeutics, Inc. (TCRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like TScan Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.